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Summary: 
Recent research has made important progress in the directed 
differentiation of human pluripotent stem cells into insulin-producing 
beta-like cells in vitro. A new study published in this issue of The EMBO 
Journal reports that timely induction of NEUROG3 expression in 
pancreatic progenitors is a crucial checkpoint for generation of 
functional human beta cells. 
 
Diabetes mellitus is a metabolic disorder of multiple etiology characterized by 
chronic hyperglycemia, which over time leads to long–term damage, 
dysfunction and failure of various organs (American Diabetes Association, 
2013). Finding ways to restore the pancreatic beta cell population in patients 
with type 1 diabetes, or replace dysfunctional beta cells in patients with type 2 
disease, remains a “holy grail” for diabetes research. Transplantation of 
cadaveric islets has provided the proof-of-concept that cell replacement 
therapy, combined with immunotherapy, represents a definitive and valuable 
treatment for diabetic patients, particularly for those suffering from type 1 
diabetes (Ryan et al, 2005). The approach has shown to restore endogenous 
beta cell function and renders patients insulin-independent for a certain 
number of months (Ryan et al, 2005). However, the widespread application of 
islet cell transplantation is still challenged by the limited supply and quality of 
donor islets, inadequate engraftment, and deleterious effects of chronic 
immunosuppression. So ways to eliminate these constrains and generate vast 
numbers of functional, glucose-responsive insulin-producing beta cells are 
under intense investigation in many laboratories around the world.  
Human pluripotent embryonic stem (ES) or induced pluripotent stem (iPS) not 
only provide tools to advance our understanding of human pancreatic 
development, but also offer a potential endless supply of insulin-producing 
cells. In the past years, great advances have been made in defining multistep 
protocols based on developmental paradigms to differentiate hESCs into 
pancreatic progenitors capable to maturate further in vivo (D'Amour et al, 
2006 ; Rezania et al, 2012; Rezania et al, 2013; Schulz et al, 2012). 
Specifically, the hESC-derived pancreatic progenitors were able to 
differentiate in vitro into a heterogeneous population, including polyhormonal 
(insulin+, glucagon+, somatostatin+) cells, which ultimately gave rise to some 
glucose-responsive, insulin-secreting eta cells capable of reversing diabetes 
months after transplantation into mice (D'Amour et al, 2006 ; Rezania et al, 
2012; Rezania et al, 2013; Schulz et al, 2012). However, full maturation of in 
vitro into bona fide transplantable beta cells has remained an elusive goal that 
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until recently has been difficult to achieve. Indeed, two recent studies focused 
on optimizing the maturation steps in vitro by systematic screen of numerous 
soluble factors (small molecules, cytokines and growth factors) on pancreatic 
progenitors (Pagliuca et al, 2014; Rezania et al, 2014). Both efforts have been 
successful and resulted in generating hESC-derived beta-like cells that 
secrete insulin in response to glucose challenge in vitro before being 
transplanted in mice (Pagliuca et al, 2014; Rezania et al, 2014). 
Monohormonal populations expressing beta cell transcription factors (e.g. 
NKX6.1+/INSULIN+ and MAFA+/INSULIN+ cells (Rezania et al, 2014) or 
NKX6.1+/C-PEPTIDE+ cells (Pagliuca et al, 2014) and with certain functional 
similarities to human beta cells were generated with an overall efficiency 
above 30%. Nevertheless, undesirable polyhormonal cells were still present, 
even though the fraction was reduced (≤15%) (Pagliuca et al, 2014; Rezania 
et al, 2014). 
Polyhormonal cells are unwanted, as they are immature cells, expressing 
multiple endocrine hormones, non-glucose responsive and negative for key 
beta cell transcription factors, including NKX6.1, which is used to monitor the 
emergence of mature beta cells (Nostro et al, 2015; Rezania et al, 2013). In 
this issue of The EMBO Journal, Russ et al. identified the problem and 
provided a solution to it, demonstrating that undesirable nonfunctional 
polyhormonal cells result from precocious induction of the endocrine program 
in PDX1+ pancreatic progenitors, which have not yet turned on NKX6.1 
expression (Russ et al, 2015). By conducting a systematic analysis of 
individual components present in established hESC differentiation protocols 
(Rezania et al, 2012; Schulz et al, 2012), the authors found that exposure of 
endodermal gut tube (GT) cultures exclusively to Retinoic Acid followed by 
EGF and KGF treatment works the best, resulting in efficient generation of 
PDX1+/NKX6.1+ pancreatic progenitor (PP) cells (90%) (Russ et al, 2015) 
(Fig. 1). By contrast, the addition of the BMP inhibitor Noggin at these early 
steps, as it is routinely used in most of the current protocols, leads to 
premature expression of the endocrine transcription factor NEUROG3, which 
favors the generation of polyhormonal cells in culture (Russ et al, 2015). Yet, 
the inhibition of BMP signaling (by Noggin or small molecule inhibitor LDN-
193189) becomes relevant afterwards, helping to push PDX1+/NKX6.1+ 
progenitors to differentiate into bona fide NEUROG3+ endocrine progenitors 
(EN) (Fig. 1). Russ et al. also demonstrated that the EN cells can make it 
further: following an additional short time in simplified culture conditions 
without growth factors, they gave rise predominantly to monohormonal insulin-
producing cells (> 20%) that show key features of a bona fide eta cell and to 
a much smaller fraction (3%) of polyhormonal cells when compared to 
previous reports. 
Overall, these findings highlight the importance of precisely recapitulating the 
temporal induction of early pancreatic progenitor fate (PDX1 > NKX6.1 > 
NEUROG3) in order to generate fully differentiated eta cells in vitro. Hence, 
Russ et al. identifies a first major bottleneck along the stepwise progression of 
hESCs toward pancreatic beta cell fate in the early specification stage – prior 
to the maturation step – (Russ et al, 2015). Similarly to the mouse embryo, in 
which the competence of pancreatic progenitors to generate distinct 
endocrine cell types changes throughout development (Johansson et al, 
2007), also in hES-derived endoderm the timely induction of NEUROG3 at a 
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precise time point is required for beta cell specification. Finally, precise 
manipulation of the appropriate signaling pathways at key developmental 
stages appears to be the “recipe for success” to overcome this bottleneck in 
vitro. In particular, this study underscores the existence of versatile functions 
of the BMP signaling during directed differentiation of hESCs into pancreatic 
fate, which is in close agreement with in vivo observations in vertebrate 
embryos (Chung et al, 2010; Wandzioch & Zaret, 2009) but at odd with most 
of the in vitro protocols currently used (D'Amour et al, 2006 ; Nostro et al, 
2015; Pagliuca et al, 2014; Rezania et al, 2014; Rezania et al, 2012; Rezania 
et al, 2013). Further clarification on the distinct temporal activities of BMP 
signaling, how BMP influences NGN3 expression at the molecular level and 
how to achieve timely but also uniform NEUROG3 activation may enhance 
the efficiency of monohormonal mature beta cells in directed differentiation of 
hESCs. The simplified differentiation protocol of Russ et al. provides an in 
vitro platform highly amenable for studying these questions in human beta cell 
specification and maturation.  
Now that significant progresses have been made towards making hESC-
derived cells with beta cell traits, a comprehensive and comparative analysis 
of 1) the various strategies and 2) of the phenotype of the different beta cell 
surrogates with human beta cell counterparts found in the body would help to 
unify the efforts and create a framework for boosting future cell therapy 
treatment for diabetes.  
 
 
 
 
 
 
 
 
Figure 1. Directed differentiation of hES cells into mature beta-like cells. 
Simplified diagram describing the new strategy reported by Russ et al (Russ 
et al, 2015) for in vitro differentiation of hESCs into pancreatic beta-like cells. 
Addition of BMP inhibitors at pancreatic progenitor stage (PP) ensures precise 
temporal activation of NEUROG3 and favors generation of monohormonal 
insulin-secreting cells versus polyhormonal cells. Commonly used 
differentiation strategy is boxed in light grey, wherein earlier inhibition of BMP 
signaling leads to premature endocrine commitment and higher number of 
polyhormonal cells.  
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